Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 5/20 | 0.46 |
| ▸ | TYK2 | P29597 | 5/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 4/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372094 | 0.89 | TYK2 (0.47) | TYK2PTGESJAK2 | |
| SCHEMBL12294718 | 0.87 | PTGES (0.48) | TYK2PTGESJAK2 | |
| SCHEMBL2371742 | 0.86 | TYK2 (0.45) | FGFR1TYK2PTGESJAK2 | |
| SCHEMBL2372692 | 0.85 | TYK2 (0.54) | TYK2PTGESJAK2JAK1DGAT1 | |
| SCHEMBL2372807 | 0.83 | PTGES (0.42) | TYK2PTGESJAK2DGAT1 | |
| SCHEMBL2371576 | 0.83 | TYK2 (0.65) | TYK2PTGESJAK2 | |
| SCHEMBL2372123 | 0.82 | TYK2 (0.60) | ABL1TYK2PTGESJAK2 | |
| SCHEMBL2372564 | 0.81 | TYK2 (0.47) | TYK2JAK2DGAT1 | |
| SCHEMBL2371222 | 0.81 | AURKB (0.44) | TYK2EGFRPTGESJAK2KDR | |
| SCHEMBL2373068 | 0.80 | TYK2 (0.49) | TYK2JAK2JAK1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2547338-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | FGFR1 722/4885SRC 164/4885ABL1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.